These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1807 related articles for article (PubMed ID: 23726587)

  • 21. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.
    Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D
    Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor.
    Kim JM; Kwon CH; Joh JW; Kang ES; Park JB; Lee JH; Kim SJ; Paik SW; Lee SK; Kim DW
    J Hepatol; 2013 Dec; 59(6):1215-22. PubMed ID: 23928408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
    Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
    Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma exchange conditioning for ABO-incompatible renal transplantation.
    Winters JL; Gloor JM; Pineda AA; Stegall MD; Moore SB
    J Clin Apher; 2004; 19(2):79-85. PubMed ID: 15274200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
    Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
    Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eight years of outcomes of the Dutch Living Donor Kidney Exchange Program.
    de Klerk M; Kal-van Gestel JA; Haase-Kromwijk BJ; Claas FH; Weimar W;
    Clin Transpl; 2011; ():287-90. PubMed ID: 22755421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates.
    Rostaing L; Maggioni S; Hecht C; Hermelin M; Faudel E; Kamar N; Sallusto F; Doumerc N; Allal A
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():165-9. PubMed ID: 25894148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
    Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up.
    Genberg H; Kumlien G; Wennberg L; Berg U; Tydén G
    Transplantation; 2008 Jun; 85(12):1745-54. PubMed ID: 18580466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and risk stratification for late antibody-mediated rejection in recipients of ABO-incompatible kidney transplants: a retrospective study.
    Lonze BE; Bae S; Kraus ES; Holechek MJ; King KE; Alachkar N; Naqvi FF; Dagher NN; Sharif A; Desai NM; Segev DL; Montgomery RA
    Transpl Int; 2017 Sep; 30(9):874-883. PubMed ID: 28403566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tailored immunosuppression after kidney transplantation - a single center real-life experience.
    Good-Weber M; Roos M; Mueller TF; Rüsi B; Fehr T
    BMC Nephrol; 2020 Nov; 21(1):501. PubMed ID: 33228545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First two ABO-incompatible living renal transplantations using splenectomy, rituximab, plasmapheresis and IVIG as a preconditioning regimen: a single center experience in the Balkans.
    Ivanovski N; Popov Z; Masin-Spasovska J; Dimcevska AH; Kolevski P
    Xenotransplantation; 2006 Mar; 13(2):123-5. PubMed ID: 16623805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Kidney transplantation from an ABO-incompatible living donor].
    Capocasale E; Iaria M; Sassi M; Dalle Valle R; Mazzoni MP; Sianesi M; Franchini M
    Ann Ital Chir; 2011; 82(4):283-7. PubMed ID: 21834478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.
    Barnett AN; Manook M; Nagendran M; Kenchayikoppad S; Vaughan R; Dorling A; Hadjianastassiou VG; Mamode N
    Transpl Int; 2014 Feb; 27(2):187-96. PubMed ID: 24188566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of accelerated acute rejection after ABO-compatible living unrelated kidney transplantation.
    Matsuo N; Yamamoto H; Kobayashi A; Yamamoto I; Mitome J; Maruyama Y; Hayakawa H; Miyazaki Y; Utsunomiya Y; Hosoya T; Yamaguchi Y
    Clin Transplant; 2009 Aug; 23 Suppl 20():23-6. PubMed ID: 19594591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
    Kayler LK; Farber JL; Colombe B; LaCava D; Friedewald JJ; Ratner LE
    Transpl Int; 2006 Feb; 19(2):128-39. PubMed ID: 16441362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption.
    Kälble F; Süsal C; Pego da Silva L; Speer C; Benning L; Nusshag C; Pham L; Tran H; Schaier M; Sommerer C; Beimler J; Mehrabi A; Zeier M; Morath C
    Front Med (Lausanne); 2021; 8():781491. PubMed ID: 34977083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation.
    Morris GP; Phelan DL; Jendrisak MD; Mohanakumar T
    Hum Immunol; 2010 Mar; 71(3):268-73. PubMed ID: 20074605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 91.